Skip to main content
Category

Treatments

Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance ResearchTreatments

Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance

*March 2019*  This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to Iressa/Tarceva/Afatinib, as many in our group queried about their options other…
laurabbook@gmail.com
March 17, 2019
Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon   ResearchTreatments

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon  

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet FDA approved.  It is currently being offered to patients across multiple…
laurabbook@gmail.com
March 14, 2019
egfr treatments lung cancer
Overcoming Resistance to Targeted Therapies in EGFR-Positive Patients ResearchTreatments

Overcoming Resistance to Targeted Therapies in EGFR-Positive Patients

*January 29, 2019* Lungevity, by Juhi Kunde.   In 2004, after the discovery of mutations in the EGFR gene in lung cancer, the FDA approved a targeted therapy that increased survival in EGFR-positive NSCLC patients. However, the tumors inevitably became resistant to the treatment, and the cancer returned unchecked. To understand…
laurabbook@gmail.com
February 3, 2019
A cancer researcher reflects on the evolution of lung cancer therapies ResearchTreatments

A cancer researcher reflects on the evolution of lung cancer therapies

*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons.   When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer were very limited. Radiation and surgery were seldom options, because in…
laurabbook@gmail.com
February 3, 2019
targeted oncology
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC ResearchTreatments

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center (MDACC) and the…
laurabbook@gmail.com
February 3, 2019
OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How? ResearchTreatments

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies for Advanced NSCLC - Shifting the Utility of Local Therapies; The…
laurabbook@gmail.com
January 5, 2019
Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer ResearchTreatments

Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer

*December 10, 2018, University of Texas M. D. Anderson Cancer Center*  Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). They believe two…
laurabbook@gmail.com
January 4, 2019
Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer ResearchTreatments

Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer

June 12 2018.  A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc. Cancer Research UK will manage the initial clinical development of AST-VAC2, a…
laurabbook@gmail.com
January 4, 2019
PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS ResearchTreatments

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living…
laurabbook@gmail.com
November 22, 2018
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors ResearchTreatments

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR T790M-negative but EGFR G724S-positive subclones and osimertinib resistance.…
laurabbook@gmail.com
November 22, 2018